Supercharged immune cells take on Hard-to-Treat breast cancer
NCT ID NCT05989828
First seen Jan 08, 2026 · Last updated May 22, 2026 · Updated 17 times
Summary
This early-phase trial tests a personalized cell therapy for people with advanced triple negative breast cancer that has stopped responding to standard treatments. Doctors take a patient's own immune cells, train them in the lab to recognize and attack cancer cells, and return them to the body. The main goals are to find the safest dose and check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
USC / Norris Comprehensive Cancer Center
RECRUITINGLos Angeles, California, 90033, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.